RxSight, Inc. (RXST): who owns it and who trades it
As of Nov 16, 2026, RXST insiders reported 3 open-market sales worth $104K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Wilterding (CFO), with $54K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling RxSight
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RXST
150 funds and institutions reported RXST shares worth $201M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 14.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.79M | 13.99% | $27.9M | +82% |
| Millennium Management LLC | 3.03M | 7.32% | $14.6M | +47% |
| No Street GP LP | 2.06M | 4.96% | $9.9M | +3% |
| Nomura Holdings Inc | 2.00M | 4.83% | $9.6M | No change |
| D. E. Shaw & Co., Inc. | 1.99M | 4.80% | $9.6M | +1% |
| Vanguard Capital Management LLC | 1.68M | 4.05% | $8.1M | -1% |
| AQR Capital Management LLC | 1.53M | 3.71% | $7.4M | +141% |
| Acadian Asset Management LLC | 1.50M | 3.63% | $7.2M | +47% |
| Federated Hermes, Inc. | 1.20M | 2.90% | $5.8M | +11% |
| Two Sigma Investments, LP | 1.15M | 2.77% | $5.5M | -12% |
| Healthcare of Ontario Pension Plan Trust Fund | 1.13M | 2.73% | $5.5M | No change |
| UBS Group AG | 1.02M | 2.45% | $4.9M | +324% |
| Jacobs Levy Equity Management, Inc | 998,569 | 2.41% | $4.8M | -6% |
| Marshall Wace, LLP | 995,916 | 2.41% | $4.8M | – |
| Geode Capital Management, LLC | 984,978 | 2.38% | $4.7M | +7% |
| State Street Corp | 851,512 | 2.06% | $4.1M | +6% |
| Point72 Asset Management, L.P. | 778,252 | 1.88% | $3.8M | +6% |
| Grandeur Peak Global Advisors, LLC | 722,440 | 1.75% | $3.5M | +55% |
| Schonfeld Strategic Advisors LLC | 701,417 | 1.69% | $3.4M | +266% |
| Citadel Advisors LLC | 700,736 | 1.69% | $3.4M | -37% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RXST insiders reported $0 of open-market purchases and $104K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ronald M MD Kurtz | Chief Medical Officer | Sale | 5,100 | $6.96 | $35.5K | Form 4 |
| Sep 2, 2026 | Mark Wilterding | CFO | Sale | 7,765 | $6.96 | $54K | Form 4 |
| Sep 2, 2026 | Ilya Goldshleger | Chief Operating Officer | Sale | 2,041 | $6.96 | $14.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark Wilterding | Chief Financial Officer | – | $54K | Sep 2, 2026 |
| Ronald M MD Kurtz | Chief Medical Officer | – | $35.5K | Sep 2, 2026 |
| Ilya Goldshleger | Chief Operating Officer | – | $14.2K | Sep 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RXST short interest
Moderate short interest. 8.7% of RXST shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 25%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.63M RXST shares were sold short, 8.7% of the shares outstanding, down 11.8% from the report before. At the average daily volume of 598,318 shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.63M | 8.67% | -12% | 598,318 | 6.1 |
| Oct 15, 2026 | 4.12M | 9.90% | +1% | 674,695 | 6.1 |
| Sep 30, 2026 | 4.09M | 9.83% | +3% | 882,847 | 4.6 |
| Sep 15, 2026 | 3.98M | 9.56% | +3% | 720,435 | 5.5 |
| Aug 31, 2026 | 3.88M | 9.32% | -9% | 837,879 | 4.6 |
| Aug 14, 2026 | 4.26M | 10.24% | +5% | 942,455 | 4.5 |
| Jul 31, 2026 | 4.06M | 9.75% | +6% | 1.01M | 4.0 |
| Jul 15, 2026 | 3.84M | 9.28% | -30% | 1.38M | 2.8 |
| Jun 30, 2026 | 5.51M | 13.32% | +32% | 1.60M | 3.4 |
| Jun 15, 2026 | 4.18M | 10.10% | +0% | 1.08M | 3.9 |
| May 29, 2026 | 4.17M | 10.08% | -14% | 695,283 | 6.0 |
| May 15, 2026 | 4.85M | 11.72% | -13% | 804,950 | 6.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
RxSight company events
RxSight filed 13 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 15, 2026LeadershipThe Board of Directors of RxSight, Inc. appointed Aziz Mottiwala to serve as the Company’s President and Chief Executive Officer, effective as of Mr. Mottiwala’s first day of employment with the Company, which is expected to be July 20, 2026, replacing Ron Kurtz, M.D. in such roles. Filing
- Jul 6, 2026AgreementWe entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd, pursuant to which we will collaborate with Alcon to develop and commercialize light-adjustable versions of certain Alcon simultaneous vision intraocular lenses by incorporating RxSight Light… Filing
- Jul 6, 2026ResultsReleased financial results. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 19, 2026LeadershipAmended an earlier report. RxSight, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission to report, among other things, the appointment of Mark Wilterding as the Company’s Chief Financial Officer. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026LeadershipThe Company appointed Mark Wilterding as its Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026, replacing Shelley Thunen in such capacities. Filing
- Dec 23, 2025LeadershipIn connection with the previously announced pending transition of Shelley Thunen from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), on December 23, 2025, RxSight, Inc. and Ms. Thunen entered into a transition agreement and release of claims… Filing
- Dec 22, 2025LeadershipShelley Thunen notified RxSight, Inc. of her intention to transition from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), effective upon the sooner of the appointment of her successor as Chief Financial Officer or January 31, 2026. Filing
- Dec 19, 2025LeadershipThe Board of Directors of RxSight, Inc. appointed Eric Weinberg to the executive officer position of Chief Business Development Officer concurrent with his transition from the Chief Commercial Officer position on the same date. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
RxSight financials
Famous investors that hold RXST
5 of the 50 well-known investors we track reported holding RXST in their latest 13F filing. The largest position is Israel Englander's, worth $10.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.14M | $10.5M | 0.0% | -29% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.43M | $7M | 0.0% | +84% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 353,962 | $1.7M | 0.0% | +169% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 258,665 | $1.3M | 0.0% | -63% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 226,993 | $1.1M | 0.0% | +61% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named RXST in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 3.4% |
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 3.4% |
| Nov 10, 2026 | Millennium Management LLC | 13G | 5.2% |
| Nov 10, 2026 | Millennium Management LLC | 13G | 5.2% |
| Nov 2, 2026 | Millennium Management LLC | 13G/A | 5.1% |
| Nov 2, 2026 | Millennium Management LLC | 13G/A | 5.1% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G/A | 8.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.9% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G/A | 8.4% |
Questions about RxSight, Inc. (RXST) stock
Who owns the most RXST stock?
The largest reported owner of RxSight, Inc. (RXST) is BlackRock, Inc., with 14.0% of the company. In total, 150 funds and institutions reported holding RXST at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RXST insiders buying or selling?
In the last 12 months, RXST insiders reported no open-market purchases and 3 sales worth $104K. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in RXST?
As of Oct 30, 2026, 3.63M RXST shares were sold short, 8.7% of the shares outstanding, down 11.8% from the report before. At the average daily volume of 598,318 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Which famous investors hold RXST?
5 of the 50 well-known investors we track reported RXST in their latest 13F filing, including Israel Englander, Steve Cohen, Paul Tudor Jones. The largest position is worth $10.5M. See all holders.
Executive pay
RxSight's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, down 33% from $7M the year before. In the last 12 months, RxSight's executives and directors bought no stock on the open market and sold $104K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.